Results 21 to 30 of about 29,994,236 (203)

Development of a latency model for HIV-1 subtype C and the impact of long terminal repeat element genetic variation on latency reversal [PDF]

Journal of Virus Eradication
Sub-Saharan Africa accounts for almost 70 % of people living with HIV (PLWH) worldwide, with the greatest numbers centred in South Africa where 98 % of infections are caused by subtype C (HIV-1C).
Shreyal Maikoo, Robert-Jan Palstra, Krista L. Dong, Tokameh Mahmoudi, Thumbi Ndung'u, Paradise Madlala   +5 more
doaj   +2 more sources

Catchet-MS identifies IKZF1-targeting thalidomide analogues as novel HIV-1 latency reversal agents. [PDF]

Nucleic Acids Res, 2022
A major pharmacological strategy toward HIV cure aims to reverse latency in infected cells as a first step leading to their elimination. While the unbiased identification of molecular targets physically associated with the latent HIV-1 provirus would be ...
Ne E, Crespo R, Izquierdo-Lara R, Rao S, Koçer S, Górska A, van Staveren T, Kan TW, van de Vijver D, Dekkers D, Rokx C, Moulos P, Hatzis P, Palstra RJ, Demmers J, Mahmoudi T.   +15 more
europepmc   +2 more sources

HSF1 inhibition attenuates HIV-1 latency reversal mediated by several candidate LRAs In Vitro and Ex Vivo. [PDF]

Proc Natl Acad Sci U S A, 2020
HIV-1 latency is a major barrier to cure. Identification of small molecules that destabilize latency and allow immune clearance of infected cells could lead to treatment-free remission.
Timmons A, Fray E, Kumar M, Wu F, Dai W, Bullen CK, Kim P, Hetzel C, Yang C, Beg S, Lai J, Pomerantz JL, Yukl SA, Siliciano JD, Siliciano RF.   +14 more
europepmc   +2 more sources

Shocking HIV-1 with immunomodulatory latency reversing agents [PDF]

Seminars in Immunology, 2021
The "shock-and-kill" strategy is one of the most explored HIV-1 cure approaches to eliminate latent virus. This strategy is based on HIV-1 reactivation using latency reversing agents (LRAs) to reactivate latent proviruses (the "shock" phase) and to induce subsequent elimination of the reactivated cells by immune responses or virus-induced cytopathic ...
Anna Kula-Pacurar, Anthony Rodari, Gilles Darcis, Carine Van Lint   +3 more
openaire   +4 more sources

Identification of celastrol as a novel HIV-1 latency reversal agent by an image-based screen. [PDF]

PLoS One, 2021
Although current antiretroviral therapies (ART) are successful in controlling HIV-1 infection, a stable viral reservoir reactivates when ART is discontinued. Consequently, there is a major research effort to develop approaches to disrupt the latent viral reservoir and enhance the immune system’s ability to clear HIV-1.
Liu H, Hu PW, Dubrulle J, Stossi F, Nikolai BC, Mancini MA, Rice AP.   +6 more
europepmc   +6 more sources

Differentiation into an Effector Memory Phenotype Potentiates HIV-1 Latency Reversal in CD4⁺ T Cells. [PDF]

J Virol, 2019
During antiretroviral therapy (ART), human immunodeficiency virus type 1 (HIV-1) persists as a latent reservoir in CD4+ T cell subsets in central memory (TCM), transitional memory (TTM), and effector memory (TEM) CD4+ T cells.
Kulpa DA, Talla A, Brehm JH, Ribeiro SP, Yuan S, Bebin-Blackwell AG, Miller M, Barnard R, Deeks SG, Hazuda D, Chomont N, Sékaly RP.   +11 more
europepmc   +2 more sources

The Current Status of Latency Reversing Agents for HIV-1 Remission [PDF]

Annual Review of Virology, 2021
Combinatory antiretroviral therapy (cART) reduces human immunodeficiency virus type 1 (HIV-1) replication but is not curative because cART interruption almost invariably leads to a rapid rebound of viremia due to the persistence of stable HIV-1-infected cellular reservoirs.
Rodari, Anthony, Darcis, Gilles, Van Lint, Carine   +2 more
openaire   +3 more sources

Lithium attenuates HIV-1 latency reversal in an autophagy-independent way. [PDF]

iScience
The major barrier to eradicate HIV-1 is its persistence in latently infected cells. Inducing deep latency to prevent HIV-1 reactivation in the absence of combined antiretroviral therapy (cART) remains a primary goal. Here, we evaluated the repurposing of lithium as an HIV-1 latency-promoting drug (LPA).
Abdalla AL, Guajardo-Contreras G, Chau BA, Niu M, Murooka T, Mouland AJ.   +5 more
europepmc   +3 more sources

The BAF complex inhibitor pyrimethamine reverses HIV-1 latency in people with HIV-1 on antiretroviral therapy [PDF]

Science Advances, 2023
Reactivation of the latent HIV-1 reservoir is a first step toward triggering reservoir decay. Here, we investigated the impact of the BAF complex inhibitor pyrimethamine on the reservoir of people living with HIV-1 (PLWH). Twenty-eight PLWH on suppressive antiretroviral therapy were randomized (1:1:1:1 ratio) to receive pyrimethamine, valproic acid ...
Prins, Henrieke A. B., Crespo, Raquel, Lungu, Cynthia, Rao, Shringar, Li, Letao, Overmars, Ronald J., Papageorgiou, Grigorius, Mueller, Yvonne M., Stoszko, Mateusz, Hossain, Tanvir, Kan, Tsung Wai, Rijnders, Bart J. A., Bax, Hannelore I., van Gorp, Eric C. M., Nouwen, Jan L., de Vries-Sluijs, Theodora E. M. S., Schurink, Carolina A. M., de Mendonça Melo, Mariana, van Nood, Els, Colbers, Angela, Burger, David, Palstra, Robert-Jan, van Kampen, Jeroen J. A., van de Vijver, David A. M. C., Mesplède, Thibault, Katsikis, Peter D., Gruters, Rob A., Koch, Birgit C. P., Verbon, Annelies, Mahmoudi, Tokameh, Rokx, Casper   +30 more
openaire   +6 more sources

Empirical PK/PD Model for Differentiating Intrinsic Dosing Rules by Therapeutic Indication With Relevance for HIV-1 Latency Reversal. [PDF]

Clin Pharmacol Ther
Romidepsin (RMD), an FDA‐approved histone deacetylase inhibitor for treating cancer, demonstrates potent latency‐reversing activity in vitro but has yielded suboptimal outcomes in kick‐and‐kill HIV‐cure trials when administered as a 5 mg/m2 infusion.
Tompkins LAR, Poliseno A, Ward A, Browne EP, Gilbert C, Sykes C, Kashuba ADM, Cottrell ML.   +7 more
europepmc   +2 more sources